- Home
- BCG vs TVGN Comparison
BCG vs TVGN Comparison
Compare BCG & TVGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | BCG | TVGN |
|---|---|---|
| Founded | 2016 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Blank Checks |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.6M | 21.3M |
| IPO Year | 2025 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BCG | TVGN |
|---|---|---|
| Price | $1.15 | $7.25 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 24.4K | 6.9K |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 112.50 | N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $187,144,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $14.56 | ★ N/A |
| Revenue Growth | ★ 10.80 | N/A |
| 52 Week Low | $1.11 | $0.14 |
| 52 Week High | $3.44 | $12.03 |
Technical Indicators
Market Signals| Indicator | BCG | TVGN |
|---|---|---|
| Relative Strength Index (RSI) | 31.86 | 49.98 |
| Support Level | N/A | $6.22 |
| Resistance Level | $1.58 | $7.66 |
| Average True Range (ATR) | 0.07 | 0.48 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 14.00 | 32.64 |
Price Performance
Historical ComparisonAbout BCG Binah Capital Group Inc.
Binah Capital Group Inc formerly Wentworth Management Services LLC is a holding company that acquires and manages businesses in the wealth management industry. The company specializes in consolidating independent broker-dealers to capture economies of scale needed to service financial advisors in today's technology-enabled regulatory environment. Wentworth's core philosophy focuses on building long-term, productive relationships with its advisor base.
About TVGN Tevogen Bio Holdings Inc.
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The first clinical product of ExacTcell, TVGN 489, is initially being developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of chronic, lingering symptoms of the disease (Long COVID). Viruses, including COVID-19, hijack cellular machinery to transform infected cells into virus production plants.